> In countries with public health care, setting the price that high will typically result in near-zero sales, I’m not sure that’s strictly true at least when i

> In countries with public health care, setting the price that high will typically result in near-zero sales, I’m not sure that’s strictly true at least when it comes to the most expensive/newly developed drugs: https://www.investigate-europe.eu/posts/deadly-prices-medicine-dealers-europe-secret-drug-negotiations https://www.investigate-europe.eu/posts/deadly-prices-medici... Doesn’t seem that massively different from the relationship between insurance companies and drug companies in the US. > In countries with public health care, setting the price that high will typically result in near-zero sales Interestingly enough it seems like the poorer Central/East European countries end up paying more than the richer ones.